ACIP Updates Recommendation on COVID-19 Vaccine Intervals
If keeping to the authorized schedule is not feasible, the second dose may be scheduled for administration up to 42 days (6 weeks) after the first dose, according to ACIP.
COVID19
MPR Weekly Dose Podcast Episode 65
On this week’s MPR pod we take a look at the current status of Johnson & Johnson’s COVID-19 vaccine candidate; Considerations in assessing blood donors during pandemic times; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling.
BinaxNOW Rapid Antigen Test Has Lower Sensitivity Than RT-PCR
Sensitivity 64.2 and 35.8 percent for specimens from symptomatic and asymptomatic persons, with near 100 percent specificity
Bamlanivimab Promising for COVID-19 Prevention in Long-Term Care Facilities
The placebo-controlled BLAZE-2 trial included 965 adults who tested negative for SARS-CoV-2 at baseline (299 residents and 666 staff) in the primary analysis for assessing prevention.
FDA: Update on Blood Donation During COVID-19 Pandemic
To date, there have been no reported cases of transfusion-transmitted coronavirus, including SARS-CoV-2.
Life Expectancy Reduced Considerably Due to COVID-19
Life expectancy at birth reduced by 1.13 years to 77.48 years; reductions greater for Blacks, Latinos versus Whites
Predictions in Medicine 2021: What Might We Expect?
An intense 2020 may be behind us, but, this year seems likely to place the COVID-19 pandemic front and center again.
MPR Weekly Dose Podcast Episode 64
This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; And the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.
Ad26.COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2
Neutralizing antibodies detected in 90 percent or more of all participants on day 29 after the first vaccine dose.
Negative COVID-19 Test to Be Required for People Flying to US
Passengers without proof of a negative test will not be allowed to board flights to America
